Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce C. Cozadd Sells 1,300 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $159.45, for a total transaction of $207,285.00. Following the completion of the sale, the chief executive officer now directly owns 278,615 shares of the company’s stock, valued at $44,425,161.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

JAZZ stock opened at $164.41 on Wednesday. Jazz Pharmaceuticals PLC has a 12 month low of $128.58 and a 12 month high of $184.00. The company has a market cap of $9.85 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 0.89 and a beta of 1.06. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The business had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same period in the prior year, the business earned $3.22 earnings per share. The business’s quarterly revenue was up 14.0% on a year-over-year basis. Equities analysts predict that Jazz Pharmaceuticals PLC will post 11.71 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $201.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday. Piper Jaffray Companies set a $213.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, October 19th. Mizuho reaffirmed a “neutral” rating and issued a $173.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, October 15th. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 28th. Finally, Leerink Swann upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $192.65.

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its position in shares of Jazz Pharmaceuticals by 300.7% in the 3rd quarter. SG Americas Securities LLC now owns 7,949 shares of the specialty pharmaceutical company’s stock valued at $1,336,000 after acquiring an additional 5,965 shares in the last quarter. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 3.5% in the 3rd quarter. LSV Asset Management now owns 298,292 shares of the specialty pharmaceutical company’s stock valued at $50,151,000 after acquiring an additional 9,956 shares in the last quarter. Systematic Financial Management LP lifted its position in shares of Jazz Pharmaceuticals by 1.0% in the 3rd quarter. Systematic Financial Management LP now owns 143,216 shares of the specialty pharmaceutical company’s stock valued at $24,079,000 after acquiring an additional 1,368 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $8,868,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Jazz Pharmaceuticals by 72.6% in the 3rd quarter. Janney Montgomery Scott LLC now owns 6,334 shares of the specialty pharmaceutical company’s stock valued at $1,065,000 after acquiring an additional 2,665 shares in the last quarter. 92.95% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This article was first posted by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://theenterpriseleader.com/2018/11/07/jazz-pharmaceuticals-plc-jazz-ceo-bruce-c-cozadd-sells-1300-shares.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply